Enliven Therapeutics
ELVN
ELVN
31 hedge funds and large institutions have $26.2M invested in Enliven Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $27K
Holders
31
Holding in Top 10
–
Calls
–
Puts
$27K
Top Buyers
| 1 | +$1.57M | |
| 2 | +$1.38M | |
| 3 | +$153K | |
| 4 |
Bank of New York Mellon
New York
|
+$95.9K |
| 5 |
Two Sigma Advisers
New York
|
+$49.3K |
Top Sellers
| 1 | -$3.08M | |
| 2 | -$523K | |
| 3 | -$429K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$411K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$206K |